13.04
-0.05 (-0.38%)
| Previous Close | 13.09 |
| Open | 13.00 |
| Volume | 466,901 |
| Avg. Volume (3M) | 591,655 |
| Market Cap | 648,291,392 |
| Price / Book | 4.61 |
| 52 Weeks Range | |
| Earnings Date | 9 Jul 2025 - 14 Jul 2025 |
| Diluted EPS (TTM) | -3.77 |
| Total Debt/Equity (MRQ) | 3.98% |
| Current Ratio (MRQ) | 10.44 |
| Operating Cash Flow (TTM) | -127.65 M |
| Levered Free Cash Flow (TTM) | -72.82 M |
| Return on Assets (TTM) | -58.15% |
| Return on Equity (TTM) | -150.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | KalVista Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.90 |
|
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.36% |
| % Held by Institutions | 113.44% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Jones Trading, 130.06%) | Buy |
| Median | 28.00 (114.72%) | |
| Low | 19.00 (Citizens Capital Markets, 45.71%) | Buy |
| Average | 25.67 (96.86%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 11.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 08 Apr 2025 | 28.00 (114.72%) | Buy | 10.32 |
| 26 Mar 2025 | 28.00 (114.72%) | Buy | 12.07 | |
| Citizens Capital Markets | 26 Mar 2025 | 19.00 (45.71%) | Buy | 12.07 |
| Jones Trading | 26 Mar 2025 | 30.00 (130.06%) | Buy | 12.07 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PALLEIKO BENJAMIN L | - | 14.76 | -7,169 | -105,814 |
| Aggregate Net Quantity | -7,169 | |||
| Aggregate Net Value ($) | -105,814 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 14.76 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PALLEIKO BENJAMIN L | Officer | 09 Jun 2025 | Sell (-) | 7,169 | 14.76 | 105,814 |
| PALLEIKO BENJAMIN L | Officer | 06 Jun 2025 | Option execute | 15,625 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |